Iterum Therapeutics Plc's (ITRM) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Iterum Therapeutics Plc  (NASDAQ: ITRM)
 



  Iterum Therapeutics Plc Outlook

On May 13 2024 the Iterum Therapeutics Plc provided following guidance

Iterum Therapeutics Plc. has recently reported their financial results for the first quarter of 2024. The company has resubmitted their New Drug Application (NDA) and is expecting action from the FDA in early Q4 2024. With a cash runway extending into 2025, including potential approval from the FDA, Iterum Therapeutics is in a strong financial position. The company is optimistic about the future and remains focused on bringing their innovative treatments to market.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.